To prevent bronchiolitis during the winter season, the Cantonal Medical Service, the Geneva University Hospitals and the Geneva Pediatric Society recommend the administration of a dose of Beyfortus® (Nirsevimab, monoclonal antibody) to all infants born from April 1, 2024.
When
Table of Contents
Table of Contents
Beyfortus® will be available during the month of October 2024. Its administration is recommended:
- in October, for babies born between April and September 2024
- from birth, for babies born between October 2024 and March 2025; treatment will be offered in maternity wards.
Comment
Beyfortus® can be safely administered at the same time as vaccines given in early childhood.
Prix
Beyfortus® preventive treatment is covered by basic insurance, with the exception of the 10% co-payment.
All about Beyfortus®
What is this treatment? Is it effective? Is it safe? Everything you need to know about Beyfortus®
And also: simple preventive measures to apply
- Before 3 months of age, limit visits to healthy adults without symptoms of cold, cough or fever.
- Wash your hands (or use an alcohol-based hand sanitizer) before and after touching your baby.
- Wear a mask yourself if you have a cold, cough or fever.
- Avoid letting siblings who have symptoms of cold, cough or fever come near him.
- If possible, avoid family gatherings and crowded public places such as supermarkets, restaurants and public transport.
– What are the benefits of administering Beyfortus® to infants during winter?
Protect Your Infant from Bronchiolitis this Winter: Beyfortus® Recommendations and Guidelines
As the winter season approaches, parents of newborns are concerned about the risk of bronchiolitis, a common and potentially severe respiratory illness in young children. To mitigate this risk, the Cantonal Medical Service, the Geneva University Hospitals, and the Geneva Pediatric Society have recommended the administration of Beyfortus® (Nirsevimab, monoclonal antibody) to all infants born from April 1, 2024. In this article, we will provide comprehensive information on Beyfortus®, its administration, and importance, as well as simple preventive measures to reduce the risk of bronchiolitis.
When to Administer Beyfortus®
Beyfortus® will be available in October 2024, and its administration is recommended in two phases:
In October 2024, for babies born between April and September 2024
From birth, for babies born between October 2024 and March 2025; treatment will be offered in maternity wards
Safety and Co-Administration with Vaccines
It is essential to note that Beyfortus® can be safely administered at the same time as vaccines given in early childhood. This ensures that your infant receives optimal protection against bronchiolitis without compromising their routine vaccination schedule.
Cost and Coverage
The preventive treatment with Beyfortus® is covered by basic insurance, with the exception of the 10% co-payment. This makes it an accessible and affordable solution for parents seeking to protect their newborns from the risks of bronchiolitis.
All About Beyfortus®
Beyfortus® is a monoclonal antibody that has been specifically designed to prevent bronchiolitis in infants. It works by targeting the respiratory syncytial virus (RSV), which is the primary cause of bronchiolitis in young children. Beyfortus® has been proven to be effective in reducing the risk of bronchiolitis and hospitalization due to RSV infection.
Numerous clinical trials have demonstrated the safety and efficacy of Beyfortus®. The treatment has been shown to reduce the risk of bronchiolitis by up to 70% and hospitalization due to RSV infection by up to 80%. Beyfortus® is administered as a single dose, providing long-term protection against bronchiolitis throughout the winter season.
Simple Preventive Measures to Reduce the Risk of Bronchiolitis
In addition to administering Beyfortus®, there are several simple preventive measures that parents can take to reduce the risk of bronchiolitis:
Practice good hygiene: Wash your hands frequently, especially before handling your infant
Avoid close contact with people who are sick
Keep your infant away from tobacco smoke and secondhand smoke
Breastfeed your infant, as breast milk contains antibodies that can help protect against RSV infection
Ensure your infant receives a healthy diet rich in fruits and vegetables
By combining these preventive measures with the administration of Beyfortus®, you can significantly reduce the risk of bronchiolitis in your infant and provide them with a healthy and safe start in life.
Conclusion
Bronchiolitis is a common and potentially severe respiratory illness in young children. The administration of Beyfortus® (Nirsevimab, monoclonal antibody) is a highly effective way to reduce the risk of bronchiolitis and hospitalization due to RSV infection. By understanding the guidelines for administration, safety, and cost, parents can make informed decisions to protect their newborns from the risks of bronchiolitis. Additionally, simple preventive measures can further reduce the risk of bronchiolitis, ensuring a healthy and safe winter season for your infant.
Recommended Reading
World Health Organization (WHO). (2020). Bronchiolitis.
Centers for Disease Control and Prevention (CDC). (2020). Respiratory Syncytial Virus (RSV).
Beyfortus® product information. (2024).
Note: The article is written in a way that it is optimized for search engines (SEO-optimized) and provides comprehensive information on the topic.
What are the benefits of administering Beyfortus to infants for bronchiolitis prevention during winter?
Protect Your Infant from Bronchiolitis this Winter: Beyfortus Recommendations and Guidelines
As the winter season approaches, parents of newborns are concerned about the risk of bronchiolitis, a common and potentially serious respiratory infection that affects infants. To prevent bronchiolitis during the winter season, the Cantonal Medical Service, the Geneva University Hospitals, and the Geneva Pediatric Society recommend the administration of a dose of Beyfortus (Nirsevimab, a monoclonal antibody) to all infants born from April 1, 2024.
When
Beyfortus will be available during the month of October 2024. Its administration is recommended:
In October, for babies born between April and September 2024
From birth, for babies born between October 2024 and March 2025; treatment will be offered in maternity wards.
Comment
Beyfortus can be safely administered at the same time as vaccines given in early childhood.
Prix
Beyfortus preventive treatment is covered by basic insurance, with the exception of the 10% co-payment.
All about Beyfortus
Beyfortus is a monoclonal antibody treatment that has been shown to be effective in preventing bronchiolitis in infants. It is a single dose, administered intramuscularly, that provides protection against respiratory syncytial virus (RSV), the primary cause of bronchiolitis. Beyfortus has been demonstrated to be safe and well-tolerated in clinical trials.
And also: simple preventive measures to apply
In addition to administering Beyfortus, there are several simple preventive measures that parents can take to reduce the risk of bronchiolitis in their infants:
Before 3 months of age, limit visits to healthy adults without symptoms of cold, cough or fever.
Wash your hands (or use an alcohol-based hand sanitizer) before and after touching your baby.
Wear a mask yourself if you have a cold, cough or fever.
Avoid letting siblings who have symptoms of cold, cough or fever come near him.
If possible, avoid family gatherings and crowded public places such as supermarkets, restaurants and public transport.
*What are the benefits
